Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT – Get Rating) was the target of a large drop in short interest in July. As of July 31st, there was short interest totalling 32,900 shares, a drop of 31.9% from the July 15th total of 48,300 shares. Based on an average trading volume of 49,200 shares, the short-interest ratio is currently 0.7 days.
Analyst Ratings Changes
Separately, TheStreet lowered Opiant Pharmaceuticals from a "c" rating to a "d+" rating in a research report on Tuesday, May 31st.
Get
Opiant Pharmaceuticals alerts:
Insiders Place Their Bets
In other news, Director Michael Sinclair sold 7,688 shares of the company's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $12.94, for a total value of $99,482.72. Following the completion of the sale, the director now owns 41,532 shares in the company, valued at approximately $537,424.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Michael Sinclair sold 7,688 shares of the business's stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $12.94, for a total transaction of $99,482.72. Following the transaction, the director now directly owns 41,532 shares in the company, valued at $537,424.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Craig A. Collard acquired 4,037 shares of the firm's stock in a transaction on Monday, June 13th. The stock was purchased at an average price of $10.94 per share, with a total value of $44,164.78. Following the purchase, the director now owns 53,822 shares in the company, valued at approximately $588,812.68. The disclosure for this purchase can be found here. Insiders have sold 23,751 shares of company stock valued at $304,412 in the last three months. 25.15% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Opiant Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of OPNT. Hillsdale Investment Management Inc. bought a new position in shares of Opiant Pharmaceuticals during the 4th quarter valued at about $108,000. JPMorgan Chase & Co. lifted its position in Opiant Pharmaceuticals by 10.7% during the first quarter. JPMorgan Chase & Co. now owns 7,466 shares of the technology company's stock valued at $160,000 after buying an additional 723 shares during the period. Advisor Group Holdings Inc. grew its holdings in Opiant Pharmaceuticals by 28.5% in the fourth quarter. Advisor Group Holdings Inc. now owns 8,125 shares of the technology company's stock worth $273,000 after purchasing an additional 1,800 shares during the period. State Street Corp grew its stake in shares of Opiant Pharmaceuticals by 10.7% in the 1st quarter. State Street Corp now owns 13,285 shares of the technology company's stock worth $285,000 after buying an additional 1,285 shares during the last quarter. Finally, Mariner LLC purchased a new position in shares of Opiant Pharmaceuticals in the 1st quarter worth about $290,000. Institutional investors own 27.93% of the company's stock.
Opiant Pharmaceuticals Stock Performance
Shares of Opiant Pharmaceuticals stock traded up $0.90 on Friday, reaching $13.48. 31,822 shares of the company traded hands, compared to its average volume of 17,959. The company has a debt-to-equity ratio of 0.35, a current ratio of 8.72 and a quick ratio of 8.72. The firm has a market capitalization of $68.48 million, a PE ratio of -3.31 and a beta of 0.52. The company has a 50 day moving average of $11.52 and a 200 day moving average of $18.20. Opiant Pharmaceuticals has a 52 week low of $7.34 and a 52 week high of $37.71.
Opiant Pharmaceuticals (NASDAQ:OPNT – Get Rating) last released its earnings results on Tuesday, May 10th. The technology company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($1.68). Opiant Pharmaceuticals had a negative return on equity of 46.15% and a negative net margin of 51.18%. The firm had revenue of $4.47 million during the quarter, compared to analysts' expectations of $7.13 million. During the same period in the prior year, the business earned ($0.66) earnings per share. Equities analysts forecast that Opiant Pharmaceuticals will post -6.21 earnings per share for the current year.
About Opiant Pharmaceuticals
(Get Rating)
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
Recommended Stories
- Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
